Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | TK2 | O00142 | 2/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CDA | P32320 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966155 | 0.84 | TYMP (0.38) | PYGMTYMPTK2MAPTCDA | |
| SCHEMBL9060322 | 0.73 | PYGM (0.49) | PYGMTK2ADKMAPTCDA | |
| SCHEMBL9064907 | 0.73 | PYGM (0.49) | PYGMTK2ADKMAPTCDA | |
| SCHEMBL10887708 | 0.69 | PYGM (0.77) | PYGMTK2 | |
| SCHEMBL10887702 | 0.69 | PYGM (0.77) | PYGMTK2 | |
| SCHEMBL11211730 | 0.68 | LMNA (0.49) | PYGMADKMAPTCDA | |
| Hydrochloric Acid SCHEMBL10886410 | 0.67 | LMNA (0.48) | PYGMADKMAPTCDA | |
| Hydrochloric Acid SCHEMBL10886418 | 0.67 | LMNA (0.48) | PYGMADKMAPTCDA | |
| SCHEMBL9092454 | 0.66 | TYMP (0.41) | PYGMTYMPMAPT | |
| SCHEMBL9060208 | 0.66 | PYGM (0.58) | PYGMTYMPTK2ADKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7118731-B2 | Drugs for the diagnosis of tissue reproductive activity or the treatment of proliferative diseases | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2006-10-10 | — | — | US | disclosed |
| EP-1270017-B1 | RADIOLABELED PYRIMIDINE NUCLEOSIDE FOR THE DIAGNOSIS OF TISSUE-REPRODUCTIVE ACTIVITY | NIHON MEDIPHYSICS CO LTD (JP) | 2006-04-12 | — | — | EP | disclosed |
| US-20030124054-A1 | Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2003-07-03 | — | — | US | disclosed |
| EP-1270017-A1 | DRUGS FOR THE DIAGNOSIS OF TISSUE-REPRODUCTIVE ACTIVITY OR THE TREATMENT OF PROLIFERATIVE DISEASES | Nihon Medi-Physics Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124054-A1 | Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases | MKI67, PCNA, NR5A1 | PYGM 1489/4885TYMP 100/4885TK2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.